In 2014, the company established a wholly-owned subsidiary, SystImmune, in Seattle, USA. Through the SystImmune R&D center, the company leads the discovery of innovative therapies and new drug pipelines during the "0 to 1" stage, as well as global clinical development and future commercialization of ongoing research products in global markets.